Capital Research Global Investors Has $33.39 Million Stock Holdings in Establishment Labs Holdings Inc. $ESTA

Key Points

• Capital Research Global Investors trimmed its stake in Establishment Labs by 20.5%, selling 209,926 shares and leaving it with 814,491 shares worth about $33.39 million (2.80% ownership).
• Analysts have been raising targets and ratings recently — the consensus is a "Moderate Buy" with an average price target of $86.86 (six Buys, one Hold, one Sell).
• In the latest quarter Establishment Labs reported EPS -$0.09 (beating estimates) and revenue of $64.62 million, up 45.2% year-over-year, though the company remains unprofitable with negative net margin and ROE.

Capital Research Global Investors trimmed its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 20.5% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 814,491 shares of the company's stock after selling 209,926 shares during the quarter. Capital Research Global Investors owned 2.80% of Establishment Labs worth $33,386,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. State of Wyoming bought a new position in Establishment Labs in the third quarter valued at approximately $71,000. Osaic Holdings Inc. increased its position in shares of Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company's stock worth $85,000 after acquiring an additional 1,800 shares in the last quarter. Brian Low Financial Group LLC acquired a new stake in shares of Establishment Labs during the third quarter worth $223,000. Private Advisor Group LLC lifted its position in Establishment Labs by 14.1% in the 3rd quarter. Private Advisor Group LLC now owns 5,450 shares of the company's stock valued at $223,000 after acquiring an additional 675 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC lifted its position in Establishment Labs by 5.8% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 6,375 shares of the company's stock valued at $261,000 after acquiring an additional 350 shares in the last quarter. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have issued reports on ESTA. Needham & Company LLC increased their target price on Establishment Labs from $84.00 to $86.00 and gave the stock a "buy" rating in a report on Tuesday, February 24th. JPMorgan Chase & Co. boosted their price target on Establishment Labs from $71.00 to $80.00 and gave the company an "overweight" rating in a report on Wednesday, December 17th. Canaccord Genuity Group upped their price objective on Establishment Labs from $85.00 to $90.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. Wall Street Zen upgraded Establishment Labs from a "hold" rating to a "buy" rating in a report on Saturday, March 7th. Finally, Stephens lifted their target price on Establishment Labs from $85.00 to $90.00 and gave the company an "overweight" rating in a research report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Establishment Labs has a consensus rating of "Moderate Buy" and an average price target of $86.86.

Establishment Labs Price Performance

NASDAQ:ESTA opened at $63.60 on Friday. The stock has a market capitalization of $1.86 billion, a PE ratio of -36.55 and a beta of 0.91. Establishment Labs Holdings Inc. has a 1-year low of $26.56 and a 1-year high of $83.31. The firm has a fifty day simple moving average of $70.36 and a 200 day simple moving average of $60.25. The company has a current ratio of 3.04, a quick ratio of 2.00 and a debt-to-equity ratio of 10.51.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.13. The firm had revenue of $64.62 million for the quarter, compared to analyst estimates of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The company's quarterly revenue was up 45.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.19) earnings per share. On average, research analysts expect that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.